What is Gilead Sciences's yeztugo — total revenues?

Gilead Sciences (GILD) reported yeztugo — total revenues of $232M in Q2 2026.

What does yeztugo — total revenues mean?

This metric represents the total gross revenue generated from the sale of the Yeztugo product line within the company's HIV therapeutic portfolio. It reflects the market adoption, pricing power, and clinical demand for this specific pharmaceutical asset. As a key component of the company's core infectious disease franchise, this revenue stream is a primary indicator of the product's lifecycle stage and competitive positioning against alternative HIV treatment regimens.

Gilead Sciences (GILD) Yeztugo — Total revenues

Screener

Other product segments

Biktarvy

$3.77B+6.9%

Descovy

$967M+48.1%

Trodelvy

$457M+25.5%

Yescarta

$346M-12.0%

Sofosbuvir/Velpatasvir

$303M-11.4%

Genvoya

$289M-23.3%

Vemlidy

$289M+14.7%

Odefsey

$239M-19.8%

Royalty, contract and other revenues

$176M+552%

Livdelzi

$167M+114%

Symtuza - Revenue share

$138M+11.3%

Other Liver Disease

$118M-4.1%

AmBisome

$110M-14.7%

Tecartus

$70M-23.9%

Other HIV

$56M-39.1%

Other

$51M-30.1%

Veklury

$23M-81.0%

Similar metrics at other companies

SNDAResident revenue — Total revenues

$108.43M+36.8%

ASSTOther revenue — Total revenues

$43K+514%

ALN

ALNYRoyalty revenue — Total revenues

$71.67M+79.3%

HContra revenue — Total revenues

-$17M-13.3%

FTAIMaintenance revenue — Total revenues

$30.6M-38.3%

FTAIOther revenue — Total revenues

$6.21M+19,923%

Other financials

Income statement

See full

Revenue$7.8B+10.2%

Gross profit$6.2B+11.5%

Operating income-$10.4B-520%

Net income-$10.5B-636%

EPS (diluted)-$8.45-642%

Balance sheet

See full

Cash & equivalents$3.2B-38.2%

Total debt$26.2B+5.2%

Total equity$11.8B-39.9%

Total assets$49.4B-11.4%

Cash flow

See full

Operating cash flow$3.6B+332%

CapEx$140.0M+30.8%

Free cash flow$3.4B+377%

Valuation

See full

Market cap$163.59B+19.3%

Enterprise value$186.66B+18.9%

P/S5.4×+0.6×

Profitability

See full

Gross margin79.6%+1.1pp

Operating margin-8.2%-36.1pp

Net margin-10.6%-32.5pp

FCF margin42.5%+10.0pp

Returns & leverage

See full

Return on equity-20.6%-53.8pp

Debt / equity2.2×+1.0×

Current ratio1.3×0.0×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 4:13 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000882095-26-000031

(in millions)	Three Months Ended June 30, 2026 / U.S.	Three Months Ended June 30, 2026 / Europe	Three Months Ended June 30, 2026 / Rest of World	Three Months Ended June 30, 2026 / Total	Three Months Ended June 30, 2025 / U.S.	Three Months Ended June 30, 2025 / Europe	Three Months Ended June 30, 2025 / Rest of World	Three Months Ended June 30, 2025 / Total
Genvoya	236	37	16	289	322	40	16	377
Odefsey	171	58	10	239	221	66	11	298
Symtuza - Revenue share(1)	105	30	3	138	88	33	3	124
Yeztugo	223	—	9	232	15	—	—	15
Other HIV(2)	23	24	10	56	50	33	9	92
Total HIV	4,659	640	393	5,693	4,096	624	368	5,088
Liver Disease
Livdelzi	147	20	—	167	74	4	—	78

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Gilead Sciences's yeztugo — total revenues?: Gilead Sciences (GILD) reported yeztugo — total revenues of $232M in Q2 2026.
What does yeztugo — total revenues mean?: This metric represents the total gross revenue generated from the sale of the Yeztugo product line within the company's HIV therapeutic portfolio. It reflects the market adoption, pricing power, and clinical demand for this specific pharmaceutical asset. As a key component of the company's core infectious disease franchise, this revenue stream is a primary indicator of the product's lifecycle stage and competitive positioning against alternative HIV treatment regimens.